SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP).
Icosavax Mourns Sudden Passing of Tadataka Yamada, M D Chairman of the Company s Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 02, 2021 16:01 ET | Source: Icosavax, Inc. Icosavax, Inc. Seattle, Washington, UNITED STATES
SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the closing of its initial public offering of 13,953,332 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,819,999 additional shares, at an initial public offering price of $15.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Icosavax, were
Amazon Prime Day Sale : Avail Amazfit s smartwatches on great discounts mybigplunge.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mybigplunge.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose
July 20, 2021 GMT
REDWOOD CITY, Calif. (BUSINESS WIRE) Jul 19, 2021
Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the release of preclinical data in nonhuman primates (NHPs) of the company’s intranasal recombinant live attenuated COVID-19 vaccine (MV-014-212). The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines. Furthermore, the data show that MV-014-212 stimulates mucosal (nasal IgA) antibodies in the upper respiratory tract, the major infection route for SARS-CoV-2, and systemic (serum neutralizing and binding I